CordenPharma and Certest Join Forces to Enhance LNP Formulation

• CordenPharma, a global CDMO, and Certest, a Spanish company, have signed a partnership agreement to enhance LNP formulation services.

• The partnership aims to add ionizable lipids to CordenPharma’s offering, closing the gap in its formulation services for biotech and pharmaceutical companies.

CordenPharma, a global CDMO specialising in the manufacture of Drug Substances (APIs) for complex modalities, and Certest, a Spanish company focused on developing new products in Drug Delivery, have announced a partnership agreement. The collaboration is set to add ionizable lipids to CordenPharma’s complex LNP formulation services, a key element that was previously missing. This addition will support biotech and pharmaceutical companies with the development, discovery, and manufacturing of xRNA / xDNA from early clinical phase to commercial.

The partnership complements CordenPharma’s recently announced strategy to address targeting with peptide-decorated LNPs and opportunities to enhance mRNA transfection with β-sitosterol. Under the agreement, Certest will provide access to their unique ionizable lipids platform, supported by in vitro / in vivo and tox data.

In turn, CordenPharma will leverage cGMP manufacturing capacities, regulatory know-how, and market access to ensure high-quality GMP supply to support customers’ products to market. Dr. Matthieu Giraud, CordenPharma’s Senior Director, Global Lipids & Carbohydrates Platform, said, “Many therapeutic domains can benefit from the newly introduced LNP formulation. We aim to consider independently each of the four pillars of an LNP formulation, namely the lipid functional excipients, to provide our customers with the most effective support in solving their therapeutic formulation challenges.”

Nelson Fernandes, CEO of Certest, added, “The world of lipid nanoparticles is changing the pharmaceutical industry today. The results have been positive, and advancements in the formulation of LNPs, along with the development of a robust library of ionizable lipids, are set to redefine the paradigm of the current situation.”